{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099184","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.112077+00:00","generated_at":"2026-05-18T00:22:35.383269+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering","bullets":["Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.","Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.","DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.","DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.","Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099184","json":"https://secwatch.observer/filing/0000950170-25-099184.json","markdown":"https://secwatch.observer/filing/0000950170-25-099184.md","text":"https://secwatch.observer/filing/0000950170-25-099184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/0000950170-25-099184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/dyn-20250728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:22:35.383269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}